Dompé offers a significant series of professional opportunities inside its various Business Units designed to ensure that it reaches its strategic objectives.
The areas of activity are:
Working in Dompé’s Marketing Department means planning and defining the most effective means of ensuring the growth of the prescription and over-the-counter (OTC) products in the portfolios of the different therapeutic areas.
Medico-scientific Information & OTC
This sector is responsible for reaching the objectives of development relating to medico-scientific information and the pharmacy channel. Its task is to define strategies and operational priorities that make it possible to make the most of the potential of the reference market.
Medical Affairs is the medico-scientific reference of excellence for the production and divulgation of clinical data. It collaborates with the scientific community in order to provide patients with drugs that are safe and capable of meeting their therapeutic needs while fully respecting the company’s values, objectives and ethical principles.
It also deals with requests from healthcare providers for scientific information concerning the drugs in the company’s portfolio.
Human Resources, Legal Affairs, Corporate Affairs and Administration Finance Controlling & Information Communication Technology work closely with top management and the functional units in order to guarantee the effective and efficient implementation of the operational plans defined by the company’s strategy.
Production. The objective of the L’Aquila production site is to guarantee the production of the Group’s drugs and assure their national and international distribution by means of continuous research aimed at process optimisation.
Biotech. The Biotech Department is responsible for producing recombinant therapeutic proteins in accordance with the highest standards of quality (GLP and cGMP).
Research & Development
The core business of Dompé’s Research & Development Department is to identify and develop innovative molecules for the treatment of rare and orphan diseases (from drug discovery to drug registration) by continuously interacting with national and international regulatory authorities (AIFA, EMEA, FDA).
Constant research in the field of new formulation guarantee the added value of the development programmes and assure the creation of new formulations of proprietary products.